Drug intelligence / Profile preview

PTI-102

Development stage: Preclinical
Lead developer: Postsurgical Therapeutics
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Local

Overview

PTI-102 is a preclinical drug candidate being developed by Postsurgical Therapeutics in collaboration with UPEX-MED for the management of pain associated with diabetic neuropathy. The therapeutic consists of an undisclosed analgesic small molecule encapsulated within a proprietary PLGA-based drug delivery system. This system is designed for local administration, either as microspheres or an in-situ forming gel, to provide sustained release of the medication directly at the site of nerve pain. By utilizing local delivery, PTI-102 aims to provide prolonged efficacy while minimizing systemic side effects. The program has successfully completed non-GLP efficacy animal testing.

Beyond the preview

Go deeper on PTI-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTI-102.

Explore the full profile